Opko Health price to free cash flow OPK

Market value divided by free cash flow over the last twelve months, since 2015.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 289×; May 2022
10-year median: 57.3×
10-year range: 32.0× to 494×
Peer median: 8.9×

Opko Health's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in May 2022, at 289×.

On the days it had one over the last ten years, its median was 57.3×, from 32.0× in Jul 2021 to 494× in Apr 2021.

Price to free cash flow over time

median 57.3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2022	289×	43.7×	412×
2021	71.2×	32.0×	494×
2020	n/m a value too high to mean anything
2019	n/m a value too high to mean anything
2018	n/m a value too high to mean anything
2017	311×	308×	336×
2016	34.7×	30.0×	40.2×
2015	38.2×	26.6×	47.1×

Against its peers

Companies in Drug Manufacturers - General nearest Opko Health's size, closest first, today.

Company	Price to free cash flow
OPKOpko Health	n/m
OMEROmeros	n/m
AMPHAmphastar Pharmaceuticals	7.0×
PCRXPacira BioSciences	8.1×
ANABAnaptysbio	n/m
PAHCPhibro Animal Health	160×
ANIPANI Pharmaceuticals	9.6×
ABUSArbutus Biopharma	n/m
COLLCollegium Pharmaceutical	2.3×
HRMYHarmony Biosciences	n/m
PBHPrestige Consumer Healthcare	9.6×
Peer median	8.9×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Opko Health

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.